Allogene Therapeutics, Inc. cotiza a 1.29 USD y tiene una capitalización bursátil de $446M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops a pipeline of multiple allogeneic CAR T cell product candidates utilizing protein engineering, gene editin…
| Periodo | 2026-08 | 2026-05 | 2026-03 | 2025-11 |
|---|---|---|---|---|
| Real | $-0.13 | $-0.18 | $-0.17 | $-0.19 |
| Estimado | $-0.15 | $-0.18 | $-0.22 | $-0.23 |
| Sorpresa | +13.3% | +0.0% | +22.7% | +17.4% |
| Métrica | ALLO | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | — | -38.6% | — |
| Net Margin | — | -33.6% | — |
| FCF Margin | — | -13.9% | — |
| ROE | -65.3% | -40.4% | -24.9% |
| ROA | -45.9% | -32.0% | -13.9% |
| Current Ratio | 7.93 | 2.84 | +5.09 |
| Debt / Equity | — | 0.28 | — |